Careers  |  Sign In  |  Register

AstraZeneca Cleared After Federal Investigation

The U.S. government has cleared AstraZeneca’s heart drug Brilinta after a controversial clinical trial in eastern Europe, a Reuters article reports. Last October, the Department of Justice launched an investigation into discrepancies between the company’s reported effectiveness and the results by an outside clinical research source.  The investigation was unusual for the company since most pharmaceutical issues lie in false advertising as opposite to suspicious data behind a license. Shares in AstraZeneca have risen since the announcement and the company hopes to rehabilitate its image amongst physicians after the setback.

Read the article published by Reuters.